AstraZeneca PLC (AZN) is a publicly traded company in the Healthcare sector, operating within the Drug Manufacturers - General industry. The company is headquartered in Cambridge, United Kingdom. The current CEO is Pascal Claude Roland Soriot.
AZN has IPO date of 1993-05-12, 94,300 full-time employees, listed on the NYSE, a market capitalization of $316.85B.
AstraZeneca PLC is a global biopharmaceutical company engaged in the discovery, development, manufacturing, and commercialization of prescription medicines. The company maintains a diverse portfolio of marketed products across multiple therapeutic areas, including cardiovascular, renal, metabolic, and oncology treatments such as Tagrisso, Imfinzi, and Lynparza, alongside vaccines and rare disease medications including Vaxzevria and Soliris. AstraZeneca operates through a network of distributors and representative offices across the United Kingdom, Europe, the Americas, Asia, Africa, and Australasia, serving both primary and specialty care physicians. The company actively pursues innovation partnerships with organizations including Neurimmune AG, BenevolentAI, and Absci Corporation to advance drug discovery and development in areas such as neurodegenerative diseases, systemic lupus erythematosus, and oncology. Headquartered in Cambridge, United Kingdom, AstraZeneca was incorporated in 1992 and adopted its current name in 1999.
